Status:

UNKNOWN

Surveillance of Association of Immune Status and Prognosis of CNS Germ Cell Tumor Survivors

Lead Sponsor:

Chengcheng Guo

Conditions:

Intracranial Germ Cell Tumor

Intracranial Germ Cell CNS Tumor, Childhood

Eligibility:

All Genders

Brief Summary

Platinum-based chemotherapy, alternating at 21-days intervals with cycles of ifosfamide, cisplatin, and etoposide (ICE) and subsequently received radiotherapy were considered as standard treatment for...

Detailed Description

Immune status influences the reaction of anti-tumor and health condition of intracranial germ cell tumor patients. Peripheral blood and cerebrospinal fluid lymphocytes subsets, cytokines reflects thos...

Eligibility Criteria

Inclusion

  • Primary diagnosis of an intracranial germ cell tumor (Histologically confirmed intracranial non-germinomatous or germinoma germ cell tumor).
  • Histologically unconfirmed pineal and/or suprasellar tumors with serum/CSF beta HCG levels greater than 50 mIU/mL or AFP levels greater than 10 ng/ml or above institutional norm.
  • No history of anti-tumor treatment
  • Female subjects of childbearing potential have a negative pregnancy test and must agree to take effective contraceptive measures during the study period and within 3 months after the last dose;
  • Be willing and able to provide written informed consent/assent for the trial

Exclusion

  • Patients with immune function deficiency : immunosuppression status, including autoimmune disease, post-operation of organ transplantation, in-taking immunosuppressive drug, human immunodeficiency virus (HIV) positive patients,
  • Known history of active tuberculosis not adequately treated or positive QuantiFERON TB Gold test.
  • Hypoproteinemia (eg, in case of severe liver disease or nephrotic syndrome) with serum albumin \<3.0 g/dL.

Key Trial Info

Start Date :

June 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2023

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT04909307

Start Date

June 1 2019

End Date

December 31 2023

Last Update

June 3 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Surveillance of Association of Immune Status and Prognosis of CNS Germ Cell Tumor Survivors | DecenTrialz